The estimated Net Worth of Donald Ferguson is at least $584 Thousand dollars as of 30 September 2005. Donald Ferguson owns over 13,000 units of Biodelivery Sciences International stock worth over $584,339 and over the last 19 years Donald sold BDSI stock worth over $0.
Donald has made over 1 trades of the Biodelivery Sciences International stock since 2005, according to the Form 4 filled with the SEC. Most recently Donald bought 13,000 units of BDSI stock worth $24,700 on 30 September 2005.
The largest trade Donald's ever made was buying 13,000 units of Biodelivery Sciences International stock on 30 September 2005 worth over $24,700. On average, Donald trades about 6,500 units every 0 days since 2005. As of 30 September 2005 Donald still owns at least 104,533 units of Biodelivery Sciences International stock.
You can see the complete history of Donald Ferguson stock trades at the bottom of the page.
Donald's mailing address filed with the SEC is 11477 OLDE CABIN ROAD, SUITE 110, SAINT LOUIS, MO, 63141.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott, and Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: